Lonza's planned acquisition of five US contract drug-manufacturing sites from Merck KGaA is winning over analysts at RBC Capital Markets, which has lifted its price target on the Swiss contract development and manufacturing organization (CDMO) to 820 Swiss francs from 760. The move reflects a view that the deal's value lies less in an immediate valuation re-rating and more in the earnings power the assets can deliver over the next few years.
What the deal means for Lonza's numbers
RBC, an investment bank, incorporated the five US facilities into its financial model, raising its 2028 sales forecast by 3% and its profit estimate by 1%. The bank also increased its revenue and earnings assumptions for 2027 and 2028, signaling that it expects the acquired sites to contribute meaningfully to Lonza's top and bottom lines in the medium term.
The bank estimates Lonza is paying roughly 9 to 12 times near-term EBITDA—a common profitability metric that excludes interest, taxes, depreciation, and amortization. That multiple is relatively modest for a CDMO deal, suggesting the purchase price may not be excessive. RBC also argued that the US sites could generate a higher peak return on invested capital (ROIC) than Lonza's Vacaville project, a major facility in California that has been a focus of investor attention.
Why the price target moved
RBC kept its valuation framework unchanged, applying the same 18 times EBITDA multiple it used before. However, it shifted to valuing Lonza on a later base year by averaging its 2027 and 2028 forecasts. That accounting choice, combined with the higher out-year earnings estimates, is what pushed the target price higher.
In other words, the bank is not arguing that Lonza deserves a richer valuation multiple. Instead, it is betting that the company's earnings will grow enough by 2027-28 to justify a higher share price at the same multiple. This makes the investment case more about execution than about a near-term re-rating.
What it means for investors
For everyday investors, the key takeaway is that RBC's optimism is conditional on Lonza successfully integrating the five US sites and ramping them to the profitability levels baked into the forecasts. The market's focus is likely to shift from the deal announcement to evidence of progress: integration milestones, capacity utilization, and margin improvement.
If Lonza delivers on those fronts, the shares could climb toward the new target. But if the sites take longer to become profitable or returns on invested capital fall short, the upside may be limited. The deal also comes against a backdrop of broader healthcare sector strength, as seen in recent earnings lifts from Eli Lilly and Merck, which have boosted investor sentiment in the space.
Lonza's move into the US market is part of a trend among CDMOs to expand capacity in response to growing demand for outsourced drug manufacturing. The company's ability to execute on this acquisition will be a key test for management and a focal point for shareholders.
Broader context
The deal also comes as Swiss inflation has been climbing, with recent data showing inflation at 1.5%, which could influence central bank policy and, in turn, currency movements that affect Lonza's earnings. However, the company's global footprint, including the new US sites, provides some natural hedging against currency swings.
For investors, the RBC update underscores the importance of looking beyond headline price targets and understanding the assumptions behind them. A higher target driven by later-year earnings estimates carries different risks than one based on a higher multiple. As always, individual investment decisions should consider one's own financial situation and risk tolerance.
